Ian B. Hollis PharmD , Douglas L. Jennings PharmD , Selim Krim MD , Van-Khue Ton MD, PhD , Anique Ducharme MD, MSc , Jennifer Cowger MD , Mary Looby PharmD , J.J. Eulert-Green MD , Neha Bansal MD , Ed Horn PharmD , Mirnela Byku MD, PhD , Jason Katz MD, MHS , C.J. Michaud PharmD , Indranee Rajapreyar MD , Patrick Campbell MD , Cassandra Vale BPharm , Richard Cosgrove PharmD , Jaime Hernandez-Montfort MD, MSc , Jessica Otero PharmD , Amanda Ingemi PharmD , Ravi K. Ratnagiri MD
{"title":"ISHLT 关于预防和管理使用耐用、持续流心室辅助装置的患者发生血液相容性相关不良事件的策略的共识声明。","authors":"Ian B. Hollis PharmD , Douglas L. Jennings PharmD , Selim Krim MD , Van-Khue Ton MD, PhD , Anique Ducharme MD, MSc , Jennifer Cowger MD , Mary Looby PharmD , J.J. Eulert-Green MD , Neha Bansal MD , Ed Horn PharmD , Mirnela Byku MD, PhD , Jason Katz MD, MHS , C.J. Michaud PharmD , Indranee Rajapreyar MD , Patrick Campbell MD , Cassandra Vale BPharm , Richard Cosgrove PharmD , Jaime Hernandez-Montfort MD, MSc , Jessica Otero PharmD , Amanda Ingemi PharmD , Ravi K. Ratnagiri MD","doi":"10.1016/j.healun.2024.04.065","DOIUrl":null,"url":null,"abstract":"<div><p>Life expectancy of patients with a durable, continuous-flow left ventricular assist device (CF-LVAD) continues to increase. Despite significant improvements in the delivery of care for patients with these devices, hemocompatability-related adverse events (HRAEs) are still a concern and contribute to significant morbility and mortality when they occur. As such, dissemination of current best evidence and practices is of critical importance. This ISHLT Consensus Statement is a summative assessment of the current literature on prevention and management of HRAEs through optimal management of oral anticoagulant and antiplatelet medications, parenteral anticoagulant medications, management of patients at high risk for HRAEs and those experiencing thrombotic or bleeding events, and device management outside of antithrombotic medications. This document is intended to assist clinicians caring for patients with a CF-LVAD provide the best care possible with respect to prevention and management of these events.</p></div>","PeriodicalId":15900,"journal":{"name":"Journal of Heart and Lung Transplantation","volume":null,"pages":null},"PeriodicalIF":6.4000,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1053249824016462/pdfft?md5=d56396032de84054e2fc4040a20a406d&pid=1-s2.0-S1053249824016462-main.pdf","citationCount":"0","resultStr":"{\"title\":\"An ISHLT consensus statement on strategies to prevent and manage hemocompatibility related adverse events in patients with a durable, continuous-flow ventricular assist device\",\"authors\":\"Ian B. Hollis PharmD , Douglas L. Jennings PharmD , Selim Krim MD , Van-Khue Ton MD, PhD , Anique Ducharme MD, MSc , Jennifer Cowger MD , Mary Looby PharmD , J.J. Eulert-Green MD , Neha Bansal MD , Ed Horn PharmD , Mirnela Byku MD, PhD , Jason Katz MD, MHS , C.J. Michaud PharmD , Indranee Rajapreyar MD , Patrick Campbell MD , Cassandra Vale BPharm , Richard Cosgrove PharmD , Jaime Hernandez-Montfort MD, MSc , Jessica Otero PharmD , Amanda Ingemi PharmD , Ravi K. Ratnagiri MD\",\"doi\":\"10.1016/j.healun.2024.04.065\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Life expectancy of patients with a durable, continuous-flow left ventricular assist device (CF-LVAD) continues to increase. Despite significant improvements in the delivery of care for patients with these devices, hemocompatability-related adverse events (HRAEs) are still a concern and contribute to significant morbility and mortality when they occur. As such, dissemination of current best evidence and practices is of critical importance. This ISHLT Consensus Statement is a summative assessment of the current literature on prevention and management of HRAEs through optimal management of oral anticoagulant and antiplatelet medications, parenteral anticoagulant medications, management of patients at high risk for HRAEs and those experiencing thrombotic or bleeding events, and device management outside of antithrombotic medications. This document is intended to assist clinicians caring for patients with a CF-LVAD provide the best care possible with respect to prevention and management of these events.</p></div>\",\"PeriodicalId\":15900,\"journal\":{\"name\":\"Journal of Heart and Lung Transplantation\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":6.4000,\"publicationDate\":\"2024-06-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S1053249824016462/pdfft?md5=d56396032de84054e2fc4040a20a406d&pid=1-s2.0-S1053249824016462-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Heart and Lung Transplantation\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1053249824016462\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Heart and Lung Transplantation","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1053249824016462","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
An ISHLT consensus statement on strategies to prevent and manage hemocompatibility related adverse events in patients with a durable, continuous-flow ventricular assist device
Life expectancy of patients with a durable, continuous-flow left ventricular assist device (CF-LVAD) continues to increase. Despite significant improvements in the delivery of care for patients with these devices, hemocompatability-related adverse events (HRAEs) are still a concern and contribute to significant morbility and mortality when they occur. As such, dissemination of current best evidence and practices is of critical importance. This ISHLT Consensus Statement is a summative assessment of the current literature on prevention and management of HRAEs through optimal management of oral anticoagulant and antiplatelet medications, parenteral anticoagulant medications, management of patients at high risk for HRAEs and those experiencing thrombotic or bleeding events, and device management outside of antithrombotic medications. This document is intended to assist clinicians caring for patients with a CF-LVAD provide the best care possible with respect to prevention and management of these events.
期刊介绍:
The Journal of Heart and Lung Transplantation, the official publication of the International Society for Heart and Lung Transplantation, brings readers essential scholarly and timely information in the field of cardio-pulmonary transplantation, mechanical and biological support of the failing heart, advanced lung disease (including pulmonary vascular disease) and cell replacement therapy. Importantly, the journal also serves as a medium of communication of pre-clinical sciences in all these rapidly expanding areas.